Limitations and Mortality in Intensive Care

Critical Illness Clinical Trial

— LIMO  

Official title:

Limitations and Mortality in Intensive Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04228380
• Other study ID #: LIMO
• Status: Completed
• Start date: March 1, 2020
• Est. completion date: August 31, 2023

Study information

• Verified date: September 2023
• Source: Göteborg University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is an observational prospective pilot-study that investigates which patient-related variables that predict a decision to limit life sustaining treatments. Some of the variables we were interested in cannot be accessed in registry data, such as frailty scale score and living at home or not. Furthermore we wanted to investigate if the variables that were independently associated with a decision to limit LST were different for critically ill patients with COVID-19 than for critically ill patients with other diagnoses in a Swedish intensive care unit during the pandemic.

Description:

Previous publications have demonstrated variability in end-of-life decision-making (ELDM) for critically ill patients (1-3).

Factors commonly described as underlying the variability in ELDM in northern Europe are patient-related factors such as age, sex, the severity of illness, frailty, chronic poor health, and diagnosis (4-6). Variability in ELDM is also caused by other less readily identifiable factors, such as preferences and experiences of the attending physicians (7-8).

When the pandemic of the coronavirus disease 2019 (COVID-19) struck worldwide, intensive care units (ICUs) were put under immense pressure, and resources were strained to their limit. More than 550 million cases and 6.3 million deaths have been reported worldwide (9). In Sweden, more than 9000 patients with COVID-19 were admitted for intensive care, dramatically increasing the demand for intensive care resources (10).

At the beginning of the pandemic, this disease was primarily unknown to physicians in the ICU, and its course and plausible patient outcomes were difficult to predict. Factors that have been demonstrated to predict poor long-term outcomes in critically ill COVID-19 patients are extensively studied. In a Swedish setting, they were found to be male sex, high age, high simplified acute physiology score (SAPS 3) (11), the month of admission, and preexisting conditions such as obesity, asthma, chronic obstructive pulmonary disease, malignancy, and immune deficiency (12).

End-of-life decisions in critically ill patients with and without COVID-19 are closely associated with short-term mortality (13-14). There are surprisingly few studies on EDLM in COVID-19 patients and whether these decisions were handled differently compared to other critically ill patients during the pandemic (15-16). It could be postulated that the process of ELDM changed during the pandemic as increased demands for intensive care caused an explicit lack of resources (17).

We hypothesised that ELDM was challenging for COVID-19 patients due to several uncertainties concerning prognostication. Therefore, we stipulated that end-of-life decisions in COVID-19 patients were made for older patients with higher frailty scores than the non-COVID-19 cohort and that end-of-life decisions were postponed to later in the course of the COVID-19 disease. We also hypothesised that a more significant proportion of patients in the COVID-19 cohort died without any end-of-life decision being made before death compared to the non-COVID-19 cohort.

In this study, we primarily aimed to investigate which independent factors predicted a decision to withdraw or withhold life-sustaining treatments (LST) in critically ill patients if these decisions were based on different variables for critically ill patients with COVID-19 compared to critically ill patients with other diagnoses in a Swedish ICU. Secondly, we aimed to investigate if ELDM was made later in the course of the disease for COVID-19 patients and if a higher proportion of COVID-19 patients died without any decision to limit LST.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: August 31, 2023
• Est. primary completion date: August 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years to 110 Years

Eligibility

Inclusion Criteria:

Patients over 65 years admitted to an intensive care unit for care other than simple monitoring or uncomplicated postoperative care.

Exclusion Criteria:

Declined consent to participate.

Related Conditions & MeSH terms

• Critical Illness

Intervention

Other:
• No intervention
No intervention

Locations

Country	Name	City	State
Sweden	Sahlgrenska University Hospital	Gothenburg

Sponsors (1)

Lead Sponsor	Collaborator
Göteborg University

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Variables that independently impact decisions to limit LST ICU's. Differences between covid-19 and non-Covid-19 patients.	Impact of gender, age, frailty, comorbidities, invasive ventilation, SAPS 3, BMI, length of stay on decisions to limit LST in critical illness in Swedish ICU's.	2020-2025
Secondary	Secondary outcomes	The secondary outcome was the time from admission to the end-of-life decision and to investigate if a higher proportion of patients in the COVID-19 cohort died without a previous decision to limit life sustaining treatments. Furthermore, we aimed to investigate if mortality differed between the groups. In addition, we aimed to investigate if survival after a decision to limit LST differed between the groups.	2020-2025